CARATTERISTICHE CLINICHE PREDITTIVE DI RISPOSTA AL RITUXIMAB IN UNA COORTE DI 322 PAZIENTI AFFETTI DA VASCULITI ANCA-ASSOCIATE
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 1 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 4 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 5 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 6 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 7 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 8 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 9 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 10 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 11 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 12 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 13 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 14 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 15 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 16 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 17 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 18 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 19 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 20 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 21 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 22 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 23 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 24 di 25.
![](https://congressi.sinitaly.org/wp-content/plugins/lazy-load/images/1x1.trans.gif?x43900)
Figura 25 di 25.
BibliografiaReferences
[1] Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. The New England journal of medicine 2010 Jul 15;363(3):221-32 (full text)
[2] Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. The New England journal of medicine 2010 Jul 15;363(3):211-20 (full text)
[3] Guillevin L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. The New England journal of medicine 2014 Nov 6;371(19):1771-80 (full text)
[4] Smith RM, Jones RB, Guerry MJ et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and rheumatism 2012 Nov;64(11):3760-9 (full text)
[5] Alberici F, Smith RM, Jones RB et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford, England) 2015 Jul;54(7):1153-60 (full text)
[6] Turner-Stokes T, Sandhu E, Pepper RJ et al. Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. Rheumatology (Oxford, England) 2014 Aug;53(8):1395-403 (full text)